查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1529617

自体细胞疗法市场规模、份额和趋势分析报告：2024-2030 年按应用、来源、最终用途、地区和细分市场进行的预测

Autologous Cell Therapy Market Size, Share & Trends Analysis Report By Application (Cancer, Neurodegenerative Disorders), Source (Bone Marrow, Mesenchymal Stem Cells), By End-use, By Region, And Segment Forecasts, 2024 - 2030
出版日期: | 出版商: Grand View Research | 英文 85 Pages | 商品交期: 2-10个工作天内

价格

自体细胞治疗市场成长与趋势：

Grand View Research 的最新报告显示，到 2030 年，全球自体细胞治疗市场预计将达到 179.7 亿美元。

预计2024年至2030年该市场将以22.20%的复合年增长率扩张。癌症、神经退化性疾病、心血管疾病、自体免疫疾病和整形外科等疾病和病症的负担日益增加，正在推动市场需求。同样，透过自体细胞疗法降低排斥风险是市场成长的关键因素之一，因为这些治疗方法是从患者来源的细胞中开发出来的，并支持体内受损组织的再生。

COVID-19 大流行期间，市场面临各种挑战，出于安全考虑，患者被限制留在家中。影响市场成长的因素包括製造障碍和医院病患流量减少。然而，在 COVID-19 之后，随着 FDA 的批准以及多种适应症治疗的新进展，市场需求正在增加。

2020 年 4 月，临床阶段生物技术公司 Hope Biosciences 证实了 HB-adMSC（Hope Bioscience 的自体脂肪间质干细胞）为针对COVID-19 提供免疫支持的有效性和安全性，并宣布FDA 批准其II 期临床试验。 2020年6月，Chiesi集团与Holostem Terapie Avanzate就Holoclar业务转让达成协议。 Holoclar 是一种用于眼表烧伤患者的自体干细胞治疗方法。两家公司都专注于旨在加速罕见疾病治疗方法的策略目标。

自体干细胞治疗市场报告亮点

  • 肿瘤学领域将主导市场，到 2023 年将占 29.9% 的份额。据美国癌症协会称，将有 1,958,310 例新癌症病例和 609,820 例死亡。
  • 2023年，骨髓细分市场占比最大，为29.9%。自体细胞疗法中的骨髓用于治疗多种疾病。
  • 到2023年，学术和研究领域将占最大份额，达到39.05%，预计2024年至2030年将快速成长。
  • 2023年北美自体细胞治疗市占比36.68%。由于大多数主要市场参与者（例如 BrainStorm Cell Therapeutics 和 Bristol Myers Squibb）都在该地区开展业务，因此市场竞争非常激烈。
  • 预计亚太地区的自体细胞治疗市场将在预测期内成长最快。这是由于疾病负担的增加、自体细胞疗法的活跃研究活动、成熟的生物技术部门的存在、研究设施的发展以及对细胞疗法的认识不断增强。

目录

第一章调查方法与范围

第 2 章执行摘要

第三章自体细胞治疗市场变数、趋势与范围

  • 市场体系展望
    • 母市场展望
    • 相关/附随市场展望
  • 市场动态
    • 市场推动要素分析
    • 市场限制因素分析
  • 自体细胞治疗市场分析工具
    • 产业分析-波特五力分析
    • PESTEL分析
    • 管道分析

第四章 自体细胞治疗市场：应用预估及趋势分析

  • 全球自体细胞治疗市场：应用仪表板
  • 全球自体细胞治疗市场：应用变化分析
  • 全球自体细胞治疗市场：依应用、收益
  • 癌症
  • 神经退化性疾病
  • 心血管疾病
  • 自体免疫疾病
  • 整形外科
  • 创伤治疗
  • 其他的

第五章自体细胞治疗市场：起源估计与趋势分析

  • 全球自体细胞治疗市场：起源仪表板
  • 全球自体细胞治疗市场：来源差异分析
  • 按来源地分類的收益
  • 骨髓
  • 表皮
  • 间质干细胞
  • 造血干细胞
  • 软骨细胞
  • 其他的

第六章自体细胞治疗市场：最终用途估计与趋势分析

  • 全球自体细胞治疗市场：最终用途仪表板
  • 全球自体细胞治疗市场：最终用途变化分析
  • 按最终用途分類的收益
  • 医院/诊所
  • 门诊中心
  • 学术/研究
  • 其他的

第七章自体细胞治疗市场：按应用、来源和最终用途分類的区域估计和趋势分析

  • 区域仪表板
  • 2018-2030 年市场规模、预测/趋势分析
  • 北美洲
  • 欧洲
  • 亚太地区
  • 拉丁美洲
  • 中东/非洲

第八章 竞争格局

  • 公司/竞争对手分类
  • 供应商情况
    • BrainStorm Cell Therapeutics
    • Holostem Terapie Avanzate SRL
    • Pharmicell Co. Inc
    • Opexa Therapeutics
    • Caladrius Biosciences Inc
    • US Stem Cell Inc
    • Lonza
    • Bristol Myers Squibb
    • Novartis AG.
    • Autolus therapeutics
    • Tego Science
    • Corning Incorporated
    • Bio Elpida
    • Vericel Corporation
    • Catalent, Inc
    • Sartorius AG
Product Code: GVR-4-68040-017-2

Autologous Cell Therapy Market Growth & Trends:

The global autologous cell therapy market size is expected to reach USD 17.97 billion by 2030, based on a new report by Grand View Research, Inc. The market is expected to expand at a CAGR of 22.20% from 2024 to 2030. The growing burden of diseases and disorders such as cancer, neurodegenerative disorders, cardiovascular disorders, autoimmune disorders, and orthopedics are the factors driving the demand for the market. Likewise, the reduced risk of autologous cell therapy rejection is one of the important factors for market growth as these therapies are developed from patient-derived cells and support the regeneration of the damaged tissues in the body.

During the COVID-19 pandemic, the market has witnessed various challenges where patients were restricted to stay at home due to safety concerns. Some factors that affected the market growth are manufacturing hurdles and reduced patient inflow in hospitals. However, post-COVID-19 the market has witnessed the demand for the market with FDA clearance and all of the new advances in treating a wide range of disease indications.

In April 2020, Hope Biosciences, a clinical-stage biotechnology company announced the FDA clearance for a phase II clinical trial evaluating the efficacy & safety of HB-adMSCs (Hope Bioscience' autologous, adipose-derived mesenchymal stem cells), to offer immune support against COVID-19. In June 2020, Chiesi Group and Holostem Terapie Avanzate mentioned the agreement for the transfer of the business branch Holoclar. The Holoclar is an autologous stem cell therapy for patients with ocular surface burns. It aims to allow both companies to focus on the strategic objective and accelerate procedures access for rare diseases.

Autologous Cell Therapy Market Report Highlights:

  • The cancer segment dominated the market and accounted for a share of 29.9% in 2023. According to the American Cancer Society, it is anticipated that 1,958,310 new instances of cancer and 609,820 fatalities due to the disease.
  • The bone marrow segment held the largest share of 29.9% in 2023. The bone marrow in autologous cell therapy has been successfully used to treat different diseases.
  • The academics & research segment held the largest share of 39.05% in 2023 and is anticipated to grow rapidly from 2024 to 2030.
  • North America autologous cell therapy market accounted for 36.68% share in 2023. The market is highly competitive since most of the major market players such as BrainStorm Cell Therapeutics and Bristol Myers Squibb operate in this region.
  • Asia Pacific autologous cell therapy market is anticipated to witness fastest growth over the forecast period. owing to the rising burden of diseases, strong research activities in autologous cell therapies, the presence of a well-established biotechnology sector, developing healthcare facilities, and growing awareness for cell therapies.

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation & Scope
  • 1.2. Segment Definitions
    • 1.2.1. Application
    • 1.2.2. Source
    • 1.2.3. End Use
    • 1.2.4. Regional scope
    • 1.2.5. Estimates and forecasts timeline
  • 1.3. Research Methodology
  • 1.4. Information Procurement
    • 1.4.1. Purchased database
    • 1.4.2. GVR's internal database
    • 1.4.3. Secondary sources
    • 1.4.4. Primary research
    • 1.4.5. Details of primary research
      • 1.4.5.1. Data for primary interviews in North America
      • 1.4.5.2. Data for primary interviews in Europe
      • 1.4.5.3. Data for primary interviews in Asia Pacific
      • 1.4.5.4. Data for primary interviews in Latin America
      • 1.4.5.5. Data for Primary interviews in MEA
  • 1.5. Information or Data Analysis
    • 1.5.1. Data analysis models
  • 1.6. Market Formulation & Validation
  • 1.7. Model Details
    • 1.7.1. Commodity flow analysis (Model 1)
    • 1.7.2. Approach 1: Commodity flow approach
    • 1.7.3. Volume price analysis (Model 2)
    • 1.7.4. Approach 2: Volume price analysis
  • 1.8. List of Secondary Sources
  • 1.9. List of Primary Sources
  • 1.10. Objectives

Chapter 2. Executive Summary

  • 2.1. Market Outlook
  • 2.2. Segment Outlook
    • 2.2.1. Application
    • 2.2.2. Source outlook
    • 2.2.3. End Use outlook
    • 2.2.4. Regional outlook
  • 2.3. Competitive Insights

Chapter 3. Autologous Cell Therapy Market Variables, Trends & Scope

  • 3.1. Market Lineage Outlook
    • 3.1.1. Parent market outlook
    • 3.1.2. Related/ancillary market outlook
  • 3.2. Market Dynamics
    • 3.2.1. Market driver analysis
      • 3.2.1.1. Numerous immunological advantages
      • 3.2.1.2. Rise in the proportion of the geriatric population across the globe
      • 3.2.1.3. Reduced risk of autologous cell therapy rejection
    • 3.2.2. Market restraint analysis
      • 3.2.2.1. High cost of treatment
      • 3.2.2.2. Regulatory challenges
  • 3.3. Autologous Cell Therapy Market Analysis Tools
    • 3.3.1. Industry Analysis - Porter's
      • 3.3.1.1. Supplier power
      • 3.3.1.2. Buyer power
      • 3.3.1.3. Substitution threat
      • 3.3.1.4. Threat of new entrant
      • 3.3.1.5. Competitive rivalry
    • 3.3.2. PESTEL Analysis
      • 3.3.2.1. Political landscape
      • 3.3.2.2. Technological landscape
      • 3.3.2.3. Economic landscape
    • 3.3.3. Pipeline Analysis

Chapter 4. Autologous Cell Therapy Market: TApplication Estimates & Trend Analysis

  • 4.1. Global Autologous Cell Therapy Market: Application Dashboard
  • 4.2. Global Autologous Cell Therapy Market: Application Movement Analysis
  • 4.3. Global Autologous Cell Therapy Market by Application, Revenue
  • 4.4. Cancer
    • 4.4.1. Cancer market estimates and forecasts 2018 to 2030 (USD Million)
  • 4.5. Neurodegenerative disorders
    • 4.5.1. Neurodegenerative disorders market estimates and forecasts 2018 to 2030 (USD Million)
  • 4.6. Cardiovascular disorders
    • 4.6.1. Cardiovascular disorders market estimates and forecasts 2018 to 2030 (USD Million)
  • 4.7. Autoimmune disorders
    • 4.7.1. Autoimmune disorders market estimates and forecasts 2018 to 2030 (USD Million)
  • 4.8. Orthopedics
    • 4.8.1. Orthopedics market estimates and forecasts 2018 to 2030 (USD Million)
  • 4.9. Wound healing
    • 4.9.1. Wound healing market estimates and forecasts 2018 to 2030 (USD Million)
  • 4.10. Others
    • 4.10.1. Others market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 5. Autologous Cell Therapy Market: Source Estimates & Trend Analysis

  • 5.1. Global Autologous Cell Therapy Market: Source Dashboard
  • 5.2. Global Autologous Cell Therapy Market: Source Movement Analysis
  • 5.3. Global Autologous Cell Therapy Market Estimates and Forecasts, By Source, Revenue (USD Million)
  • 5.4. Bone Marrow
    • 5.4.1. Bone marrow market estimates and forecasts 2018 to 2030 (USD Million)
  • 5.5. Epidermis
    • 5.5.1. Epidermis market estimates and forecasts 2018 to 2030 (USD Million)
  • 5.6. Mesenchymal stem cells
    • 5.6.1. Mesenchymal stem cells market estimates and forecasts 2018 to 2030 (USD Million)
  • 5.7. Haematopoietic stem cells
    • 5.7.1. Haematopoietic stem cells market estimates and forecasts 2018 to 2030 (USD Million)
  • 5.8. Chondrocytes
    • 5.8.1. Chondrocytes market estimates and forecasts 2018 to 2030 (USD Million)
  • 5.9. Others
    • 5.9.1. Others market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 6. Autologous Cell Therapy Market: End Use Estimates & Trend Analysis

  • 6.1. Global Autologous Cell Therapy Market: End Use Dashboard
  • 6.2. Global Autologous Cell Therapy Market: End Use Movement Analysis
  • 6.3. Global Autologous Cell Therapy Market Estimates and Forecasts, by End Use, Revenue (USD Million)
  • 6.4. Hospitals & Clinics
    • 6.4.1. Hospitals & clinics market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.5. Ambulatory Centers
    • 6.5.1. Ambulatory centers market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.6. Academics & Research
    • 6.6.1. Academics & research market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.7. Others
    • 6.7.1. Others market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 7. Autologous Cell Therapy Market: Regional Estimates & Trend Analysis by Application, Source, and End Use

  • 7.1. Regional Dashboard
  • 7.2. Market Size, & Forecasts Trend Analysis, 2018 to 2030:
  • 7.3. North America
    • 7.3.1. U.S.
      • 7.3.1.1. Key country dynamics
      • 7.3.1.2. Regulatory framework/ reimbursement structure
      • 7.3.1.3. Competitive scenario
      • 7.3.1.4. U.S. market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.3.2. Canada
      • 7.3.2.1. Key country dynamics
      • 7.3.2.2. Regulatory framework/ reimbursement structure
      • 7.3.2.3. Competitive scenario
      • 7.3.2.4. Canada market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.3.3. Mexico
      • 7.3.3.1. Key country dynamics
      • 7.3.3.2. Regulatory framework/ reimbursement structure
      • 7.3.3.3. Competitive scenario
      • 7.3.3.4. Mexico market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.4. Europe
    • 7.4.1. UK
      • 7.4.1.1. Key country dynamics
      • 7.4.1.2. Regulatory framework/ reimbursement structure
      • 7.4.1.3. Competitive scenario
      • 7.4.1.4. UK market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.4.2. Germany
      • 7.4.2.1. Key country dynamics
      • 7.4.2.2. Regulatory framework/ reimbursement structure
      • 7.4.2.3. Competitive scenario
      • 7.4.2.4. Germany market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.4.3. France
      • 7.4.3.1. Key country dynamics
      • 7.4.3.2. Regulatory framework/ reimbursement structure
      • 7.4.3.3. Competitive scenario
      • 7.4.3.4. France market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.4.4. Italy
      • 7.4.4.1. Key country dynamics
      • 7.4.4.2. Regulatory framework/ reimbursement structure
      • 7.4.4.3. Competitive scenario
      • 7.4.4.4. Italy market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.4.5. Spain
      • 7.4.5.1. Key country dynamics
      • 7.4.5.2. Regulatory framework/ reimbursement structure
      • 7.4.5.3. Competitive scenario
      • 7.4.5.4. Spain market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.4.6. Norway
      • 7.4.6.1. Key country dynamics
      • 7.4.6.2. Regulatory framework/ reimbursement structure
      • 7.4.6.3. Competitive scenario
      • 7.4.6.4. Norway market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.4.7. Sweden
      • 7.4.7.1. Key country dynamics
      • 7.4.7.2. Regulatory framework/ reimbursement structure
      • 7.4.7.3. Competitive scenario
      • 7.4.7.4. Sweden market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.4.8. Denmark
      • 7.4.8.1. Key country dynamics
      • 7.4.8.2. Regulatory framework/ reimbursement structure
      • 7.4.8.3. Competitive scenario
      • 7.4.8.4. Denmark market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.5. Asia Pacific
    • 7.5.1. Japan
      • 7.5.1.1. Key country dynamics
      • 7.5.1.2. Regulatory framework/ reimbursement structure
      • 7.5.1.3. Competitive scenario
      • 7.5.1.4. Japan market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.5.2. China
      • 7.5.2.1. Key country dynamics
      • 7.5.2.2. Regulatory framework/ reimbursement structure
      • 7.5.2.3. Competitive scenario
      • 7.5.2.4. China market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.5.3. India
      • 7.5.3.1. Key country dynamics
      • 7.5.3.2. Regulatory framework/ reimbursement structure
      • 7.5.3.3. Competitive scenario
      • 7.5.3.4. India market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.5.4. Australia
      • 7.5.4.1. Key country dynamics
      • 7.5.4.2. Regulatory framework/ reimbursement structure
      • 7.5.4.3. Competitive scenario
      • 7.5.4.4. Australia market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.5.5. South Korea
      • 7.5.5.1. Key country dynamics
      • 7.5.5.2. Regulatory framework/ reimbursement structure
      • 7.5.5.3. Competitive scenario
      • 7.5.5.4. South Korea market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.5.6. Thailand
      • 7.5.6.1. Key country dynamics
      • 7.5.6.2. Regulatory framework/ reimbursement structure
      • 7.5.6.3. Competitive scenario
      • 7.5.6.4. Thailand market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.6. Latin America
    • 7.6.1. Brazil
      • 7.6.1.1. Key country dynamics
      • 7.6.1.2. Regulatory framework/ reimbursement structure
      • 7.6.1.3. Competitive scenario
      • 7.6.1.4. Brazil market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.6.2. Argentina
      • 7.6.2.1. Key country dynamics
      • 7.6.2.2. Regulatory framework/ reimbursement structure
      • 7.6.2.3. Competitive scenario
      • 7.6.2.4. Argentina market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.7. MEA
    • 7.7.1. South Africa
      • 7.7.1.1. Key country dynamics
      • 7.7.1.2. Regulatory framework/ reimbursement structure
      • 7.7.1.3. Competitive scenario
      • 7.7.1.4. South Africa market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.7.2. Saudi Arabia
      • 7.7.2.1. Key country dynamics
      • 7.7.2.2. Regulatory framework/ reimbursement structure
      • 7.7.2.3. Competitive scenario
      • 7.7.2.4. Saudi Arabia market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.7.3. UAE
      • 7.7.3.1. Key country dynamics
      • 7.7.3.2. Regulatory framework/ reimbursement structure
      • 7.7.3.3. Competitive scenario
      • 7.7.3.4. UAE market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.7.4. Kuwait
      • 7.7.4.1. Key country dynamics
      • 7.7.4.2. Regulatory framework/ reimbursement structure
      • 7.7.4.3. Competitive scenario
      • 7.7.4.4. Kuwait market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 8. Competitive Landscape

  • 8.1. Company/Competition Categorization
  • 8.2. Vendor Landscape
    • 8.2.1. List of key distributors and channel partners
    • 8.2.2. Key customers
    • 8.2.3. Key company market share analysis, 2023
    • 8.2.4. BrainStorm Cell Therapeutics
      • 8.2.4.1. Company overview
      • 8.2.4.2. Financial performance
      • 8.2.4.3. Product benchmarking
      • 8.2.4.4. Strategic initiatives
    • 8.2.5. Holostem Terapie Avanzate S.R.L
      • 8.2.5.1. Company overview
      • 8.2.5.2. Financial performance
      • 8.2.5.3. Product benchmarking
      • 8.2.5.4. Strategic initiatives
    • 8.2.6. Pharmicell Co. Inc
      • 8.2.6.1. Company overview
      • 8.2.6.2. Financial performance
      • 8.2.6.3. Product benchmarking
      • 8.2.6.4. Strategic initiatives
    • 8.2.7. Opexa Therapeutics
      • 8.2.7.1. Company overview
      • 8.2.7.2. Financial performance
      • 8.2.7.3. Product benchmarking
      • 8.2.7.4. Strategic initiatives
    • 8.2.8. Caladrius Biosciences Inc
      • 8.2.8.1. Company overview
      • 8.2.8.2. Financial performance
      • 8.2.8.3. Product benchmarking
      • 8.2.8.4. Strategic initiatives
    • 8.2.9. U.S. Stem Cell Inc
      • 8.2.9.1. Company overview
      • 8.2.9.2. Financial performance
      • 8.2.9.3. Product benchmarking
      • 8.2.9.4. Strategic initiatives
    • 8.2.10. Lonza
      • 8.2.10.1. Company overview
      • 8.2.10.2. Financial performance
      • 8.2.10.3. Product benchmarking
      • 8.2.10.4. Strategic initiatives
    • 8.2.11. Bristol Myers Squibb
      • 8.2.11.1. Company overview
      • 8.2.11.2. Financial performance
      • 8.2.11.3. Product benchmarking
      • 8.2.11.4. Strategic initiatives
    • 8.2.12. Novartis AG.
      • 8.2.12.1. Company overview
      • 8.2.12.2. Financial performance
      • 8.2.12.3. Product benchmarking
      • 8.2.12.4. Strategic initiatives
    • 8.2.13. Autolus therapeutics
      • 8.2.13.1. Company overview
      • 8.2.13.2. Financial performance
      • 8.2.13.3. Product benchmarking
      • 8.2.13.4. Strategic initiatives
    • 8.2.14. Tego Science
      • 8.2.14.1. Company overview
      • 8.2.14.2. Financial performance
      • 8.2.14.3. Product benchmarking
      • 8.2.14.4. Strategic initiatives
    • 8.2.15. Corning Incorporated
      • 8.2.15.1. Company overview
      • 8.2.15.2. Financial performance
      • 8.2.15.3. Product benchmarking
      • 8.2.15.4. Strategic initiatives
    • 8.2.16. Bio Elpida
      • 8.2.16.1. Company overview
      • 8.2.16.2. Financial performance
      • 8.2.16.3. Product benchmarking
      • 8.2.16.4. Strategic initiatives
    • 8.2.17. Vericel Corporation
      • 8.2.17.1. Company overview
      • 8.2.17.2. Financial performance
      • 8.2.17.3. Product benchmarking
      • 8.2.17.4. Strategic initiatives
    • 8.2.18. Catalent, Inc
      • 8.2.18.1. Company overview
      • 8.2.18.2. Financial performance
      • 8.2.18.3. Product benchmarking
      • 8.2.18.4. Strategic initiatives
    • 8.2.19. Sartorius AG
      • 8.2.19.1. Company overview
      • 8.2.19.2. Financial performance
      • 8.2.19.3. Product benchmarking
      • 8.2.19.4. Strategic initiatives

List of Tables

  • Table 1 List of abbreviation
  • Table 2 North America autologous cell therapy market, by region, 2018 - 2030 (USD Million)
  • Table 3 North America autologous cell therapy market, by application, 2018 - 2030 (USD Million)
  • Table 4 North America autologous cell therapy market, by source, 2018 - 2030 (USD Million)
  • Table 5 North America autologous cell therapy market, by end use, 2018 - 2030 (USD Million)
  • Table 6 U.S. autologous cell therapy market, by application, 2018 - 2030 (USD Million)
  • Table 7 U.S. autologous cell therapy market, by source, 2018 - 2030 (USD Million)
  • Table 8 U.S. autologous cell therapy market, by end use, 2018 - 2030 (USD Million)
  • Table 9 Canada autologous cell therapy market, by application, 2018 - 2030 (USD Million)
  • Table 10 Canada autologous cell therapy market, by source, 2018 - 2030 (USD Million)
  • Table 11 Canada autologous cell therapy market, by end use, 2018 - 2030 (USD Million)
  • Table 12 Mexico autologous cell therapy market, by application, 2018 - 2030 (USD Million)
  • Table 13 Mexico autologous cell therapy market, by source, 2018 - 2030 (USD Million)
  • Table 14 Mexico autologous cell therapy market, by end use, 2018 - 2030 (USD Million)
  • Table 15 Europe autologous cell therapy market, by region, 2018 - 2030 (USD Million)
  • Table 16 Europe autologous cell therapy market, by application, 2018 - 2030 (USD Million)
  • Table 17 Europe autologous cell therapy market, by source, 2018 - 2030 (USD Million)
  • Table 18 Europe autologous cell therapy market, by end use, 2018 - 2030 (USD Million)
  • Table 19 Germany autologous cell therapy market, by application, 2018 - 2030 (USD Million)
  • Table 20 Germany autologous cell therapy market, by source, 2018 - 2030 (USD Million)
  • Table 21 Germany autologous cell therapy market, by end use, 2018 - 2030 (USD Million)
  • Table 22 UK autologous cell therapy market, by application, 2018 - 2030 (USD Million)
  • Table 23 UK autologous cell therapy market, by source, 2018 - 2030 (USD Million)
  • Table 24 UK autologous cell therapy market, by end use, 2018 - 2030 (USD Million)
  • Table 25 France autologous cell therapy market, by application, 2018 - 2030 (USD Million)
  • Table 26 France autologous cell therapy market, by source, 2018 - 2030 (USD Million)
  • Table 27 France autologous cell therapy market, by end use, 2018 - 2030 (USD Million)
  • Table 28 Italy autologous cell therapy market, by application, 2018 - 2030 (USD Million)
  • Table 29 Italy autologous cell therapy market, by source, 2018 - 2030 (USD Million)
  • Table 30 Italy autologous cell therapy market, by end use, 2018 - 2030 (USD Million)
  • Table 31 Spain autologous cell therapy market, by application, 2018 - 2030 (USD Million)
  • Table 32 Spain autologous cell therapy market, by source, 2018 - 2030 (USD Million)
  • Table 33 Spain autologous cell therapy market, by end use, 2018 - 2030 (USD Million)
  • Table 34 Denmark autologous cell therapy market, by application, 2018 - 2030 (USD Million)
  • Table 35 Denmark autologous cell therapy market, by source, 2018 - 2030 (USD Million)
  • Table 36 Denmark autologous cell therapy market, by end use, 2018 - 2030 (USD Million)
  • Table 37 Sweden autologous cell therapy market, by application, 2018 - 2030 (USD Million)
  • Table 38 Sweden autologous cell therapy market, by source, 2018 - 2030 (USD Million)
  • Table 39 Sweden autologous cell therapy market, by end use, 2018 - 2030 (USD Million)
  • Table 40 Norway autologous cell therapy market, by application, 2018 - 2030 (USD Million)
  • Table 41 Norway autologous cell therapy market, by source, 2018 - 2030 (USD Million)
  • Table 42 Norway autologous cell therapy market, by end use, 2018 - 2030 (USD Million)
  • Table 43 Asia Pacific autologous cell therapy market, by region, 2018 - 2030 (USD Million)
  • Table 44 Asia Pacific autologous cell therapy market, by application, 2018 - 2030 (USD Million)
  • Table 45 Asia Pacific autologous cell therapy market, by source, 2018 - 2030 (USD Million)
  • Table 46 Aisa Pacific autologous cell therapy market, by end use, 2018 - 2030 (USD Million)
  • Table 47 China autologous cell therapy market, by application, 2018 - 2030 (USD Million)
  • Table 48 China autologous cell therapy market, by source, 2018 - 2030 (USD Million)
  • Table 49 China autologous cell therapy market, by end use, 2018 - 2030 (USD Million)
  • Table 50 Japan autologous cell therapy market, by application, 2018 - 2030 (USD Million)
  • Table 51 Japan autologous cell therapy market, by source, 2018 - 2030 (USD Million)
  • Table 52 Japan autologous cell therapy market, by end use, 2018 - 2030 (USD Million)
  • Table 53 India autologous cell therapy market, by application, 2018 - 2030 (USD Million)
  • Table 54 India autologous cell therapy market, by source, 2018 - 2030 (USD Million)
  • Table 55 India autologous cell therapy market, by end use, 2018 - 2030 (USD Million)
  • Table 56 South Korea autologous cell therapy market, by application, 2018 - 2030 (USD Million)
  • Table 57 South Korea autologous cell therapy market, by source, 2018 - 2030 (USD Million)
  • Table 58 South Korea autologous cell therapy market, by end use, 2018 - 2030 (USD Million)
  • Table 59 Australia autologous cell therapy market, by application, 2018 - 2030 (USD Million)
  • Table 60 Australia autologous cell therapy market, by source, 2018 - 2030 (USD Million)
  • Table 61 Australia autologous cell therapy market, by end use, 2018 - 2030 (USD Million)
  • Table 62 Thailand autologous cell therapy market, by application, 2018 - 2030 (USD Million)
  • Table 63 Thailand autologous cell therapy market, by source, 2018 - 2030 (USD Million)
  • Table 64 Thailand autologous cell therapy market, by end use, 2018 - 2030 (USD Million)
  • Table 65 Latin America autologous cell therapy market, by region, 2018 - 2030 (USD Million)
  • Table 66 Latin America autologous cell therapy market, by application, 2018 - 2030 (USD Million)
  • Table 67 Latin America autologous cell therapy market, by source, 2018 - 2030 (USD Million)
  • Table 68 Latin America autologous cell therapy market, by end use, 2018 - 2030 (USD Million)
  • Table 69 Brazil autologous cell therapy market, by application, 2018 - 2030 (USD Million)
  • Table 70 Brazil autologous cell therapy market, by source, 2018 - 2030 (USD Million)
  • Table 71 Brazil autologous cell therapy market, by end use, 2018 - 2030 (USD Million)
  • Table 72 Argentina autologous cell therapy market, by application, 2018 - 2030 (USD Million)
  • Table 73 Argentina autologous cell therapy market, by source, 2018 - 2030 (USD Million)
  • Table 74 Argentina autologous cell therapy market, by end use, 2018 - 2030 (USD Million)
  • Table 75 MEA autologous cell therapy market, by region, 2018 - 2030 (USD Million)
  • Table 76 MEA autologous cell therapy market, by application, 2018 - 2030 (USD Million)
  • Table 77 MEA autologous cell therapy market, by source, 2018 - 2030 (USD Million)
  • Table 78 MEA autologous cell therapy market, by end use, 2018 - 2030 (USD Million)
  • Table 79 South Africa autologous cell therapy market, by application, 2018 - 2030 (USD Million)
  • Table 80 South Africa autologous cell therapy market, by source, 2018 - 2030 (USD Million)
  • Table 81 South Africa autologous cell therapy market, by end use, 2018 - 2030 (USD Million)
  • Table 82 Saudi Arabia autologous cell therapy market, by application, 2018 - 2030 (USD Million)
  • Table 83 Saudi Arabia autologous cell therapy market, by source, 2018 - 2030 (USD Million)
  • Table 84 Saudi Arabia autologous cell therapy market, by end use, 2018 - 2030 (USD Million)
  • Table 85 UAE autologous cell therapy market, by application, 2018 - 2030 (USD Million)
  • Table 86 UAE autologous cell therapy market, by source, 2018 - 2030 (USD Million)
  • Table 87 UAE autologous cell therapy market, by end use, 2018 - 2030 (USD Million)
  • Table 88 Kuwait autologous cell therapy market, by application, 2018 - 2030 (USD Million)
  • Table 89 Kuwait autologous cell therapy market, by source, 2018 - 2030 (USD Million)
  • Table 90 Kuwait autologous cell therapy market, by end use, 2018 - 2030 (USD Million)

List of Figures

  • Fig. 1 Market research process
  • Fig. 2 Data triangulation techniques
  • Fig. 3 Primary research pattern
  • Fig. 4 Primary interviews in North America
  • Fig. 5 Primary interviews in Europe
  • Fig. 6 Primary interviews in APAC
  • Fig. 7 Primary interviews in Latin America
  • Fig. 8 Primary interviews in MEA
  • Fig. 9 Market research approaches
  • Fig. 10 Value-chain-based sizing & forecasting
  • Fig. 11 QFD modeling for market share assessment
  • Fig. 12 Market formulation & validation
  • Fig. 13 Autologous cell therapy market: market outlook
  • Fig. 14 Autologous cell therapy competitive insights
  • Fig. 15 Parent market outlook
  • Fig. 16 Related/ancillary market outlook
  • Fig. 17 Autologous cell therapy market driver impact
  • Fig. 18 Autologous cell therapy market restraint impact
  • Fig. 19 Autologous cell therapy market: Application movement analysis
  • Fig. 20 Autologous cell therapy market: Application outlook and key takeaways
  • Fig. 21 Cancer market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 22 Neurodegenerative disorders market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 23 Cardiovascular disorders market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 24 Autoimmune disorders market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 25 Orthopedics market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 26 Wound healing market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 27 Others market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 28 Autologous cell therapy market: Source movement analysis
  • Fig. 29 Autologous cell therapy market: Source outlook and key takeaways
  • Fig. 30 Bone marrow market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 31 Epidermis market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 32 Mesenchymal stem cells market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 33 Haematopoietic stem cells market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 34 Chondrocytes market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 35 Others market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 36 Autologous cell therapy market: End use movement analysis
  • Fig. 37 Autologous cell therapy market: End use outlook and key takeaways
  • Fig. 38 Hospitals & clinics market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 39 Ambulatory centers market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 40 Academics & research market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 41 Others market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 42 Global autologous cell therapy market: Regional movement analysis
  • Fig. 43 Global autologous cell therapy market: Regional outlook and key takeaways
  • Fig. 44 Global autologous cell therapy market share and leading players
  • Fig. 45 North America, by country
  • Fig. 46 North America market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 47 U.S. key country dynamics
  • Fig. 48 U.S. market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 49 Canada key country dynamics
  • Fig. 50 Canada market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 51 Mexico key country dynamics
  • Fig. 52 Mexico market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 53 Europe market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 54 UK key country dynamics
  • Fig. 55 UK market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 56 Germany key country dynamics
  • Fig. 57 Germany market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 58 France key country dynamics
  • Fig. 59 France market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 60 Italy key country dynamics
  • Fig. 61 Italy market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 62 Spain key country dynamics
  • Fig. 63 Spain market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 64 Denmark key country dynamics
  • Fig. 65 Denmark market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 66 Sweden key country dynamics
  • Fig. 67 Sweden market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 68 Norway key country dynamics
  • Fig. 69 Norway market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 70 Asia Pacific market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 71 China key country dynamics
  • Fig. 72 China market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 73 Japan key country dynamics
  • Fig. 74 Japan market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 75 India key country dynamics
  • Fig. 76 India market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 77 Thailand key country dynamics
  • Fig. 78 Thailand market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 79 South Korea key country dynamics
  • Fig. 80 South Korea market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 81 Australia key country dynamics
  • Fig. 82 Australia market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 83 Latin America market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 84 Brazil key country dynamics
  • Fig. 85 Brazil market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 86 Argentina key country dynamics
  • Fig. 87 Argentina market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 88 Middle East and Africa market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 89 South Africa key country dynamics
  • Fig. 90 South Africa market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 91 Saudi Arabia key country dynamics
  • Fig. 92 Saudi Arabia market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 93 UAE key country dynamics
  • Fig. 94 UAE market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 95 Kuwait key country dynamics
  • Fig. 96 Kuwait market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 97 Market share of key market players- autologous cell therapy market